Schomäcker K, Franke W G, Mäding P, Shukla S K, Weiss S, Limouris G S, Jantsch K
Klinik und Poliklinik für Nuklearmedizin, Universität zu Köln.
Nuklearmedizin. 1993 Feb;32(1):23-6.
It is well known that after application of radioactive complexes for tumour diagnosis or therapy, such as 67Ga-citrate or radiolanthanide complexes (167Tm- or 169Yb-nitrilotriacetate, -citrate, -alpha-hydroxyisobutyrate, 90Y-citrate, etc.) activity is accumulated not only in the tumour but also in other organs, above all liver and bone. This is the main obstacle to their medical use. Recently published results encouraged us to use ethylenediaminetetramethylene phosphonate (EDTMP) for the reduction of extratumoural liver activity. The results show that even small amounts of EDTMP (1-2 mg/kg BW) reduce the activity deposition in the liver by about one order of magnitude. EDTMP provoked elimination of activity from tumour, skeleton and other tissues but not to the same extent as from the liver. Tumor/liver activity ratios > 5 are achievable in this manner.
众所周知，在应用放射性复合物进行肿瘤诊断或治疗后，比如柠檬酸镓或放射性镧系元素复合物（167Tm-或169Yb-次氮基三乙酸、-柠檬酸、-α-羟基异丁酸、90Y-柠檬酸等），放射性不仅会在肿瘤中蓄积，还会在其他器官中蓄积，尤其是肝脏和骨骼。这是它们在医学应用中的主要障碍。最近发表的结果促使我们使用乙二胺四亚甲基膦酸盐（EDTMP）来降低肝脏外的放射性。结果表明，即使是少量的EDTMP（1-2毫克/千克体重）也能使肝脏中的放射性沉积减少约一个数量级。EDTMP促使肿瘤、骨骼和其他组织中的放射性排出，但程度与肝脏不同。通过这种方式可实现肿瘤/肝脏放射性比值>5。
